Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Bristol-Myers Squibb continues to search for new ET antagonists

Sep. 27, 1996

Calcium-antagonist effects of estrogen

Sep. 20, 1996

PLC Systems can halt randomization to medical therapy in TMR trial

Sep. 20, 1996

AMI and magnesium supplementation

Sep. 20, 1996

Use of bisaramil in oxidative stress-related conditions

Sep. 20, 1996

Valaciclovir for restenosis

Sep. 20, 1996

Renin inhibitors in cardiovascular disease

Sep. 20, 1996

Zambon's ACE/NEP inhibitors for cardiovascular indications

Sep. 20, 1996

Daiichi's broad cardiovascular pipeline

Sep. 13, 1996

Roberts cleared to market cardiovascular orphan drug

Sep. 13, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Harbour Biomed closes busy year with $1B+ BMS deal
BioWorld
Harbour Biomed has added another collaboration to its end-of-year dealmaking, this time with Bristol Myers Squibb Co. (BMS) to develop multispecific antibodies....
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...